Gastrointestinal tumors
Conditions
Interventions
Regular group:Intraoperative neuromuscular monitoring is performed. Neuromuscular blocking agents are supplemented according to the TOF value (if the TOF count is >= 2, 1/3 to 1/2 of the induction dos
Quantitative Monitoring Group:Intraoperative neuromuscular monitoring was also performed, and continued in the PACU without coverage. Anesthesiologists administered an appropriate dose of neostigmine
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-65 years undergoing elective laparoscopic gastrointestinal tumor surgery; 2. ASA I-III grade
Exclusion criteria
Exclusion criteria: 1. Body Mass Index (BMI) >= 35 kg/m²; 2. Patients with neuromuscular diseases, hand injuries, or other conditions that affect grip strength measurement; 3. Pregnant or lactating women; 4. Patients with a history of allergy to cisatracurium or neostigmine; 5. Severe diseases, including severe pulmonary inflammation, severe chronic obstructive pulmonary disease (COPD) (GOLD III or IV, or requiring (non-invasive) ventilation and/or oxygen therapy at home), severe heart disease (New York Heart Association Class III or IV), severe liver disease (e.g., liver failure), chronic renal failure (glomerular filtration rate < 30 mL/min/1.73 m²); 6. Patients currently participating in research;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of residual muscle relaxation;Hospitalization expenses; | — |
Secondary
| Measure | Time frame |
|---|---|
| grip strength;Extubation time;Antagonism - extubation time;PACU stay time;hypoxemia;Pulmonary complications 7 days after surgery;length of hospital stay; | — |
Countries
China
Contacts
Public ContactZhang Zhong
Xiangya Hospital of Central South University
Outcome results
None listed